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KSHV-encoded bZip protein, namely K8, is a regulatory protein with multiple functions in immediate-early and delayed-early stages of
viral life cycle. Here we report that K8 gene is expressed in both immediate-early and delayed-early phases and the transcription in different
phases is controlled by distinct promoters, yielding two transcripts, an immediate-early mRNA of 1.5 kb and a delayed-early mRNA of 1.3
kb. The transcription from the immediate-early promoter is inducible by sodium butyrate or 12-O-tetradecanoylphorbol-13-acetate (TPA), but
not responsive to ORF50 (Rta). The delayed-early promoter of K8 shows little response to sodium butyrate and TPA, but can be fully
induced by ORF50 (Rta). In the immediate-early promoter, a 20-bp region containing two consensus Sp-1 binding sites was found to be
crucial for the basal transcription and sodium butyrate induction of the promoter. In addition, mutagenesis analyses identified three ORF50
(Rta) responsive elements (RREs) in the delayed-early promoter and their roles in ORF50-dependent transactivation were investigated. The
differential regulation of K8 gene expression may represent a strategy in that the virus fine-tunes the levels of K8 protein in different stages
or for distinct functions. The elucidation of K8 gene expression regulation helps in understanding roles of K8 in viral replication and
pathogenicity.
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Kaposi’s sarcoma-associated herpesvirus (KSHV), also
called human herpesvirus-8 (HHV-8), is a newly identified
gammaherpesvirus, belonging to Rhadinovirus genus
(Chang et al., 1994; Moore et al., 1996). Epidemiological
studies suggest that this virus is an etiologic agent of
Kaposi’s sarcoma (KS) (Ambroziak et al., 1995), primary
effusion lymphoma (PEL) (Cesarman et al., 1995a), and
multicentric Castleman’s diseases (MCD) (Soulier et al.,
1995). KSHV is able to transform human endothelial cells
(ECs) efficiently. Infection of primary human endothelial
cells by purified KSHV causes long-term proliferation and
survival of these cells, which are associated with the acqui-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: yuan2@pobox.upenn.edu (Y. Yuan).sition of telomerase activity and anchorage-independent
growth (Flore et al., 1998). Therefore, KSHV is a human
tumor virus.
As a gammaherpesvirus, KSHV has two phases in its life
cycle: latency and lytic replication. KSHV establishes latent
infection in lymphoid cells. In latently infected cells that
contain a limited number of the viral genomes, no infectious
virus is produced. Only a few of viral genes are expressed
during latency and are called latent genes. When latency is
disrupted, KSHV switches to the lytic phase (Miller et al.,
1997; Renne et al., 1996). Some chemical agents such as
TPA, sodium butyrate, and ionomycin as well as humoral
factors including interferon g and other cytokines are able
to induce lytic replication of KSHV (Chang et al., 2000;
Miller et al., 1997; Renne et al., 1996). In the lytic phase,
the virus expresses its lytic genes in a temporal and
sequential order. A few viral genes are expressed indepen-
dently of de novo protein synthesis, and are classified as
immediate-early genes. Delayed-early genes are expressed
slightly later, and their expression is not affected by
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expressed after viral DNA synthesis, and their expression
is, in general, blocked in the presence of inhibition of viral
DNA synthesis.
Reactivation of herpesviruses is initiated and controlled
by a few regulatory proteins encoded by viral immediate-
early (IE) genes. IE genes are the first class of the viral
genes expressed after primary infection or reactivation. As
their transcription does not require prior viral protein syn-
thesis, this class of genes is experimentally defined by their
transcription following primary infection or reactivation in
the presence of inhibition of protein synthesis. In a previous
study, we identified a few immediate-early genes in the
KSHV genome (Zhu et al., 1999). Among these IE genes,
ORF50 encodes a transactivator, namely Rta (standing for
replication and transcription activator). It has been shown
that expression of Rta in primary effusion lymphoma cell
lines harboring KSHV in latent stage activates expression of
downstream delayed-early and late viral lytic genes and
drives viral lytic cascade to completion (Lukac et al., 1998;
Sun et al., 1998).
The KSHV genome encodes a bZip protein, namely K8
or RAP (replication-associated protein). K8 mRNA is high-
ly spliced, which generates three splice variants as a result
of alternative splicing. K8a is the major form, which codes
for a 237-amino-acid protein with a basic-leucine zipper
domain near its C-terminus and an acidic domain near its N-
terminus. Such a structure was found in many transcription-
al regulators that compose a large bZip family. The two
other variants, K8h and K8g, encode proteins sharing the N-
terminal portion with K8a, but lacking the C-terminal Zip
domain (Lin et al., 1999; Zhu et al., 1999). K8 protein,
especially the a form, displays limited similarity to the Zta
protein of Epstein–Barr Virus and the c-Jun protooncogene
product (Lin et al., 1999; Zhu et al., 1999). Because of
analogous genome location, similar splicing pattern and
homologous protein structure with respect to EBV Zta
protein, K8 is believed to be the KSHV analogue of Zta.
The Zta is encoded by an EBV immediate-early gene
BZLF1. Three functions have been found associated with
Zta protein. (i) Zta is a transcriptional activator that activates
the viral lytic gene expression cascade and initiates the
switch of EBV from latency to lytic life cycle (Miller,
1990); (ii) Zta causes host cell cycle arrest at G0/G1 (Cayrol
and Flemington, 1996); (iii) Zta binds to EBV ori-Lyt and
the binding is essential for viral lytic DNA replication
(Fixman et al., 1995). The former two functions appear to
be required for viral lytic replication in immediate-early
stage, while the latter function is exerted in delayed-early
time. KSHV K8 was found to bind to the origin of lytic viral
DNA replication (ori-Lyt) of KSHV (Lin et al., 2003). In
addition, K8 causes cell cycle arrest at G1 phase through
induction of C/EBP-a and p21 (Wu et al., 2002). In terms of
transcriptional activity, although no transcriptional activa-
tion has been found with K8 so far, it was reported that K8
interacts with Rta (ORF50) and represses the transcriptionof viral delayed-early genes by Rta (Izumiya et al., 2003;
Liao et al., 2003).
Given that K8 is a protein with multiple functions in
different stages of viral cycle and that the expression pattern
of its gene is very complex structurally and temporally,
delineation of mechanisms that regulate K8 expression is
central for understanding the role of the viral protein in
KSHV replication and pathogenesis. The present study
aimed at understanding the regulation of K8 gene expres-
sion in KSHV life cycle. We characterized K8 expression
patterns in immediate-early (IE) and delayed-early (DE)
phases and found that transcription of K8 gene is controlled
by two promoters, yielding two transcripts, an immediate-
early mRNA of 1.5 kb and a delayed-early mRNA of 1.3 kb.
We analyzed the promoter sequences that control K8 ex-
pression in different phases of viral life cycle and identified
critical regulatory elements in these promoters. This study
demonstrated a mechanism for differential regulation of K8
genes in IE and DE phases.Results
Kinetics of 1.5-kb immediate-early and 1.3-kb delayed-early
K8 mRNA expression in PEL cells
To examine the expression pattern of K8 gene, Northern
blotting analysis was performed with BC-1 and BCBL-1
cells, of which both carry KSHV in latent stage. Poly(A+)
RNA was prepared from BC-1 cells that had been induced
with sodium butyrate (3 mM) for 4 and 20 h as well as from
BCBL-1 cells treated with TPA (20 ng/ml) for 4 and 20 h in
the absence or presence of cycloheximide (50 Ag/ml).
Cycloheximide was added 4 h before induction. Our previ-
ous study showed that cycloheximide at 50 Ag/ml is able to
block cell protein synthesis within 30 min as indicated by
very low percentage (<5%) of 35S-methionine incorporation
by treated cells (Zhu et al., 1999). The blot was hybridized
with a single-stranded DNA probe complementary to K8
mRNA in the coding region. Two transcripts of 3.6 and 1.5
kb in size were detected in sodium butyrate-induced BC-1
cells as early as at 4 h post-induction. The induction of the
transcription of these two mRNAs was not affected in the
presence of cycloheximide, therefore being classified as
immediate-early (IE) transcript (Fig. 1). The 3.6-kb IE
transcript has been characterized and known to be a bicis-
tronic mRNA and encode ORF50 and K8 open reading
frames (Zhu et al., 1999). The 1.5-kb IE mRNA was
recently reported and encodes K8 bZip protein (Saveliev
et al., 2002). In addition, a 1.3-kb transcript was detected
and behaved as a delayed-early mRNA because the induc-
tion of this transcript was strongly inhibited by the treatment
of cycloheximide (Fig. 1). The 1.3 DE mRNA was also
reported previously and encodes K8 open reading frame
(Lin et al., 1999). The 1.5-kb IE and 1.3-kb DE K8 mRNAs
differ in their 5V proximal sequences. In other words, these
Fig. 1. Northern analysis of transcripts containing K8 open reading frame. Poly (A+) RNAs were isolated from BC-1 cells that had been treated with sodium
butyrate for 4 or 20 h and from BCBL-1 cells that had been induced with TPA in the absence or presence of cycloheximide as indicated above each lane. These
RNAs were separated on a 1.0% agarose– formaldehyde gel and transferred onto nytran membranes. The membranes were probed with 32P-labeled single-
stranded DNA probes that is complementary to K8 coding sequence. Molecular marker: 0.24–9.5-kb RNA ladder.
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initiation sites, one ranging between nucleotide 74589 and
74602, another at or near 74845 (Saveliev et al., 2002). The
transcription of these two immediate-early mRNAs (3.6-kb
ORF50/K8 and 1.5-kb K8 mRNAs) was found to be tightly
controlled in the latent stage in BC-1 cells. In contrast, a
considerable level of 1.3-kb K8 mRNA was detected in the
latent stage (before induction) (Fig. 1). The immediate-early
3.6 and 1.5-kb mRNAs and the delayed-early 1.3-kb mRNA
were also detected in TPA-induced BCBL-1 cells. Although
BCBL-1 cells were sensitive to the toxicity of cyclohexi-
mide as previously reported by us and others (Lukac et al.,
1998; Zhu et al., 1999) and little mRNA can be detected in
BCBL-1 cells in the presence of 50 Ag/ml cycloheximide,
the 1.5-kb K8 mRNA was clearly shown in 4 h post-
induction in the presence of cycloheximide (Fig. 1).
The transcription of K8 is controlled by two promoters,
immediate-early and delayed-early
The 1.5-kb K8 mRNA is an immediate-early (IE) tran-
script, while 1.3-kb K8 mRNA is a delayed-early (DE)
transcript. This notion, together with the fact that these two
mRNA use different transcription initiation sites, suggested
that the syntheses of these two mRNAs are under the controlof different promoters. To prove this idea, we assayed the
upstream sequences of these two transcription initiation sites
for promoter activities. If the transcription of the 1.5-kb IE
and 1.3 DE K8 mRNAs are indeed controlled by distinct
promoters, an IE promoter activity and a DE promoter
activity were anticipated to be detected in these two sequen-
ces, respectively. A 500-bp sequence upstream of the tran-
scription initiation site for 1.5-kb K8 mRNA (nucleotides
74125–74629) and a 250-bp sequence in front of the 1.3-kb
K8 mRNA coding region (nucleotides 74596–74849) were
cloned into the pGL3-basic vector right in front of the firefly
luciferase coding sequence. These constructs were designat-
ed PK8-IE500 and PK8-DE250, respectively. These two
reporter plasmids, along with an ORF50 promoter reporter
construct (P50), were introduced into BL41 cells by electro-
poration. The transfected cells were treated with sodium
butyrate, TPA, ionomycin, and their combinations. These
chemicals were reported to be able to induce KSHV reacti-
vation (Chang et al., 2000; Miller et al., 1997; Renne et al.,
1996). As illustrated in Fig. 2A, PK8-IE500 was found to be
responsive to sodium butyrate and TPA. Although ionomycin
appears not to induce this promoter, it can synergize the
induction with TPA. The induction pattern of this K8 pro-
moter closely resembles that of the ORF50 promoter, an IE
promoter. Therefore, the promoter for 1.5-kb K8 mRNA is an
Fig. 2. Induction of two K8 promoters with chemical inducers and by ORF50 (Rta) protein. (A) Reporter plasmids containing firefly luciferase gene under
control of two K8 promoters (PK8-IE500 and PK8-DE250) were used to cotransfect BL-41 cells by electroporation. Renilla luciferase plasmid was included in
each transfection as an internal control. Transfected cells were then treated with sodium butyrate, TPA, ionomycin, and their combinations as indicated. At 48
h posttransfection, dual luciferase assays were performed. Fold of induction of a reporter was calculated by dividing the normalized firefly luciferase activity of
the reporter in a chemically treated cells by that in untreated cells. (B) BL41 cells were cotransfected with K8 promoter reporters and pCR3.1-ORF50 or empty
pCR3.1 vector. At 48 h posttransfection, cells were harvested for dual luciferase assays. Fold activation of a reporter by ORF50 was calculated by dividing the
normalized firefly luciferase activity of the reporter in pCR3.1-ORF50-transfected cells by that in pCR3.1-transfected cells. The promoters for ORF50 (P50)
and ORF59 (P59) were included as controls.
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response to these chemicals (Fig. 2A).
Then, we examined whether these K8 promoters are
responsive to ORF50 (Rta), which is a transcription activa-
tor and known to up-regulate many delayed-early viral
genes (Lukac et al., 1998; Sun et al., 1998). The K8 reporter
constructs were introduced into BL41 cells together with
pCR3.1-ORF50 or empty pCR3.1 plasmids. An ORF59
promoter construct (P59) was included as a control as it
represents a standard delayed-early promoter. A luciferaseassay showed that the immediate-early K8 promoter (PK8-
IE500) was not responsive to ORF50 (Rta). In contrast, the
promoter for 1.3-kb mRNAwas activated by ORF50 to 470-
fold. As a control, ORF50 activated the promoter for
ORF59, known as a delayed-early promoter (Lukac et al.,
1998), to 84-fold. Taken together, we conclude that the
promoter for 1.3-kb K8 mRNA is a delayed-early promoter.
The classification of these two K8 promoters is consistent
with the expression patterns of 1.5- and 1.3-kb K8 mRNAs
as illustrated by the Northern blot analysis (Fig. 1). Overall,
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two transcripts, an immediate-early mRNA of 1.5 kb and a
delayed-early mRNA of 1.3 kb. The nucleotide sequences of
these two promoters are illustrated in Fig. 3.
Characterization of K8 IE promoter
The transcription initiation site for the 1.5-kb K8 IE
mRNA has been mapped to nucleotide 74589 in a
previous study (Saveliev et al., 2002). Analysis of the
sequence of K8 IE promoter did not reveal a TATA box,
suggesting that K8 IE promoter is a TATA-less promoter.
This feature shows an analogy with other KSHV IE
promoters including promoters for ORF50 and ORF45,
that are also TATA-less promoters (Lu et al., 2003; our
unpublished data). To map the elements in the K8 IE
promoter that confer responsiveness to sodium butyrate
and TPA induction, four progressive deletion constructs of
the promoter were generated as illustrated in Fig 4A.
BL41 cells were transfected with these deletion mutants
and the transfected cells were treated with sodium buty-
rate or TPA. As shown in Fig. 4B, deletion of the region
between nucleotides 500 and 360 (relative to nucleo-
tide 74589, the transcription initiation site for the 1.5-kb
K8 mRNA) increased the sodium butyrate and TPA-
induced luciferase activities two- and threefold, respec-
tively, suggesting a negative regulatory element in the
region between 500 and 360. When the region be-
tween 360 and 230 was deleted, the reporter response
to sodium butyrate and TPA decreased two- and threefold,
respectively. In addition, removal of the DNA sequence
between nucleotides 130 and 80 resulted in a greaterFig. 3. Nucleotide sequence of the K8 promoter region. The nucleotide numbers
(Russo et al., 1996). The numbers above sequence refer to the number of nucle
represent the translation start codon of K8 protein. Transcription initiation sites of
arrows. Potential ORF50/Rta responsive elements (RREs) and putative binding sdecrease in response of the promoter to both butyrate and
TPA. Thus, these two regions appeared to carry butyrate
and TPA-responsive elements. The DNA sequence be-
tween nucleotides 230 and 130 had no effect on the
responsiveness to these chemical inducers (Fig. 4B).
Because PK8-IE130 contains the smallest promoter
region that retains responsiveness to sodium butyrate and
TPA induction, we further analyze the region between
130 and+1 for potential responsive elements. Inspection
of the nucleotide sequence of the region revealed a potential
CREB binding motif at 82. In addition, two potential GC
boxes (Sp-1 binding sites) were located downstream at 29
and 44. To assess the functions of these motifs in the K8
IE promoter, two deletion mutants were designed and
constructed (Fig. 5A). One had the CREB consensus
sequence deliberately deleted (PK8-IE230DCREB), and
the other had the region containing GC boxes removed
(PK8-IE230DGC). In BL41 cells, deletion of CREB motif
resulted in a reduction of basal transcription activity (the
transcription activity before the induction by butyrate) to
the level of empty plasmid pGL-3. However, the mutant can
still be induced by butyrate by 17-fold. In contrast, removal
of the region that contains two GC boxes abolished both
basal transcription and responsiveness to butyrate induction.
The PK8-IE230DGC mutant behaved like empty pGL-3
(Fig 5B).
Characterization of K8 DE promoter
First, two reporter constructs of K8 delayed-early pro-
moter, pK8-DE700 and pK8-DE250 that contain 700- and
250-bp sequences upstream of K8 DE transcription initia-on the left are the KSHV genome numbers according to GenBank U75698
otide upstream ( ) of transcription start sites. The boldfaced letters ATG
immediate-early (IE) and delayed-early (DE) transcriptions are indicated by
ites of transcription factors are boxed.
Fig. 4. Deletion analysis of K8 IE promoter for inductivities by sodium butyrate and TPA. (A) Schematic illustration of K8 IE promoter and its deletion
mutants. (B) Each construct was introduced into BL41 cells by electroporation as described in Materials and methods. Transfected cells were then treated with
sodium butyrate or TPA. At 48 h posttransfection, dual luciferase assays were performed and the fold of transactivation was calculated by comparing the
normalized firefly luciferase activity of the reporter in cells treated with butyrate or TPA with that in untreated cells.
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for transcription activities in the presence and absence of
ORF50 (Rta). These two constructs were introduced into
BL41 cells together with pCR3.1-ORF50 or empty pCR3.1
vector and the results showed that pK8-DE700 and pK8-
DE250 were induced by ORF50 101- and 425-fold, respec-
tively. Similar results were obtained when these constructs
were introduced into BJAB (another Burkitt’s lymphoma
cells) and 293 (human kidney epithelial cell) cells. These
data suggest a negative element present between 700 and
250. Given that pK8-DE250 does not have any over-
lapping sequence with K8 immediate-early promoter and
retains full delayed-early promoter activity in respect of
responsiveness to ORF50 (Rta) transactivation, we used this
construct as a standard K8 DE promoter for further studies.
A series of deletion mutants were constructed of the K8 DE
promoter as illustrated in Fig. 6A and analyzed in BL41
cells for their effects on the DE promoter activity. Deletion
from the nucleotide 250 to 147 caused a sixfoldreduction of responsiveness to ORF50. Deletion from
nucleotides 147 to 114 resulted an additional eightfold
reduction of the responsiveness, retaining only 2.1% of the
activity of PK8-DE250. Further deletions to 95 and 58
brought about further reductions of the promoter activities
by four- to sixfold, leaving only 0.4–0.6% of the activity of
PK8-DE250 (Fig. 6B). According to these data, the frag-
ments in the regions between 250 and 95 clearly
contribute to ORF50 responsiveness and harbor ORF50
responsive element(s).
To further characterize the K8 DE promoter and identify
the core sequence(s) responsible for ORF50 (Rta) induction,
we searched the 250-bp DNA sequence (250 to 1) for
potential ORF50 responsive sequences by comparing the
250 bp with other KSHV promoter sequences that have
been known to serve as ORF50 (Rta) responsive elements
(or RREs) for apparent homology in primary nucleotide
sequence. The comparison revealed three potential RREs.
The first one is located between 72 and 61 and contains
Fig. 5. Mutational analysis of CREB motif and Sp-1 binding sites in the KSHV K8 IE promoter. (A) Locations of the putative CREB motif and Sp-1 binding
sites in the K8 IE promoter, as well as deletion mutations. (B) Each construct was introduced into BL41 cells by electroporation. Transfected cells were then
treated with sodium butyrate or TPA. At 48 h posttransfection, dual luciferase assays were performed and relative luciferase activities were obtained by
comparing the normalized firefly luciferase activities of reporters in chemically treated and untreated cells with that of empty pGL-3 vector in untreated BL41
cells.
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found the similarity of this motif with an ORF50 responsive
element (50RE) in the ORF57 promoter and showed that
this motif could be bound by ORF50 and conferred a
responsiveness to ORF50 induction in a heterologous pro-
moter (Lukac et al., 2001). We designated this potential
RRE motif K8 RRE-I. The second potential RRE (desig-
nated K8 RRE-II) shares a sequence homology with an
ORF50 responsive region in the vIRF (K9) gene promoter
(K9RRE-II) (Ueda et al., 2002). Inspection of the sequence
surrounding the homologous motif revealed a palindromic
sequence between 133 and 95. The third potential RRE
(K8 RRE-III) is located between nucleotides 161 and
171, and also shares a sequence homology with the K9
RRE-II. In addition, an RBP-Jn binding motif (5VTGGGAA
3V) was found adjacent to K8 RRE-III. RBP-Jn was found to
interact with ORF50/Rta and play a role in ORF50-mediated
gene activation (Liang et al., 2002). To determine the
importance of these three potential RREs in ORF50-medi-
ated transactivation in the K8 promoter, we deliberately
deleted each of these RRE sequences from the K8 DE
promoter and examine the functional consequences. First,
the RRE-I element was deleted from PK8-DE250 and PK8-
DE147 reporter constructs and the mutants were designated
PK8-DE250D1 and PK8-DE147D1. To our surprise, remov-
al of the RRE-I from these two constructs showed trivialeffects in ORF50 transactivation (Fig. 7). Second, the RRE-
II sequence was also internally deleted in PK8-DE250 and
PK8-DE147 reporter constructs, and these mutants were
designated PK8-DE250D2 and PK8-DE147D2. When
cotransfected with pCR3.1-ORF50 into BL41 cells, both
PK8-DE250D2 and PK8-DE147D2 displayed almost no
transcription activity in comparison to their parental con-
structs (PK8-DE250 and PK8-DE147). These data suggest
that the RRE-II is a crucial cis-acting element for ORF50
transactivation. Then, the RRE-III (including RBP-Jn mo-
tif), in between nucleotides 161 and 182, was deleted in
the PK8-DE250. The resultant construct, PK8-DE250D3,
was used to cotransfect BL41 with ORF50 expression
vector and showed a 2.5-fold reduction of the promoter
activity (Fig. 7).
All the K8 DE promoter-derived reporter constructs
(including these progressive and internal deletions) were
also analyzed for the responsiveness to ORF50 in BJAB
cells. The results were very similar to these in BL41 cells
(data not shown). In summary, although both K8 RRE-II
and III contribute to ORF50-mediated activation of K8
delayed-early promoter, RRE-II appears to be critical for
responsiveness to ORF50. The RRE-I has little effect on the
promoter in B cells. When this article was under review,
Seaman and Quinlivan (2003) reported that removal of K8
RRE-I resulted in no reduction of the ORF50 responsive-
Fig. 6. Deletion analysis of K8 DE promoter for sequences responsive to ORF50 activation. (A) Schematic illustration of K8 DE promoter and its deletion
mutants. (B) Each construct was transfected into BL41 cells with pCR3.1-ORF50 or empty pCR3.1 by electroporation as described in Materials and methods.
Forty-eight hours posttransfection, cells were harvested, lysates were prepared, and luciferase activities were assayed. The fold of transactivation was calculated
by comparing the normalized firefly luciferase activity of the reporter in pCR3.1-ORF50-transfected cells with that in pCR3.1-transfected cells.
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KSHV-negative Burkitt’s lymphoma line. They also found
that deletion of the sequence between 110 and 100, the
right half of the RRE-II palindrome, brought about a
significant reduction in the transcription activity of the
promoter, retaining 20% of activity of the wild-type pro-
moter in DG-75 (Seaman and Quinlivan, 2003).
Differential regulation of K8 DE promoter in B cells and
non-B cells
Our data that RRE-I has the least effect on ORF50-
mediated transcription among three RREs found in K8 DE
promoter appears not consistent with previous reports on the
promoter. The RRE-I was first reported by Lukac et al.
(2001) and mutation in the 12-bp motif resulted in a
reduction of the promoter activation by 70% in CV-1 cells.
One possible explanation is that these three RREs in K8 DE
promoter are differentially utilized in B cells and non-B
cells. In other words, these RREs contribute to ORF50activation differently in different cell environments. To
examine this hypothesis, we analyzed these K8 DE promot-
er-derived reporter constructs in 293 cells for their respon-
siveness to ORF50. The results are shown in Fig. 8. In 293
cells, deletion of a fragment between 250 and 147
(which had RRE-III deleted) caused a reduction of lucifer-
ase activity by 13-fold. Deletion from nucleotide 147 to
95 (which removed RRE-II) reduced ORF50 inductivity
by only less than 40%. Further deletion to nucleotide 58
(which had RRE-I deleted) brought about a great loss of the
activity by 54-fold (Fig. 8A). This result suggests that the
RRE-1 seems to play a greater role in response to ORF50
transactivation in 293 cells than in B cells. In contrast, the
RRE-II becomes less crucial for the ORF50-dependent
activation of the promoter in 293 cells. Assays with the
internal deletion of each RREs also showed that removal of
RRE-I from PK8-DE250 (PK8-DE250D1) had greater
effects on the promoter in 293 cells than that in B cells.
For example, PK8-DE250D1 displayed very little difference
from PK8-DE250 in response to ORF50 in B cells (Fig.
Fig. 7. Responsiveness to ORF50 of internal deletion mutants of K8 DE promoter. The K8 DE promoter and its derivatives are illustrated schematically in panel
A. The potential RRE core elements are marked with boxes. K8 promoter luciferase reporter and its mutants shown in panel Awere cotransfected with pCR3.1-
ORF50 or pCR3.1 empty plasmid into BL41 cells. Luciferase activities were analyzed by the dual-luciferase reporter assay (B). Relative luciferase activities
were measured as fold activity relative to the basal level of luciferase activity in cells that are cotransfected with blank plasmids. The values represent the
average of two experiments.
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a significant reduction (by 50%) in comparison to PK8-
DE250 in ORF50-mediated transcription activities in 293
cells (Fig. 8B). This result suggested that the RRE-I con-
tributes more to ORF50 activation in 293 (non-B) cells.
Although deletion of RRE-II (PK8-DE250D2) caused a
significant reduction in ORF50 responsiveness, the mutant
still remained 12% promoter activity in response to ORF50
in 293 cells, in contrast to that in BL41 and BJAB cells
where the ORF50 responsiveness of the mutant (PK8-
DE250D2) was completely lost. The RRE-III plays a similar
role in BL41 and 293 cells without much discrimination.There is no structural similarity between K8 RRE-I and
RRE-II/-III. It was reported that ORF50 bound to K8 RRE-I
to activate the promoter (Lukac et al., 2001), while ORF50
activated K9 gene through an RRE, which is identical to K8
RRE-II, by a non-DNA binding mechanism (Ueda et al.,
2002). In addition, it was recently shown that K8 RRE-I
overlapped with a C/EBP binding site and ORF50 (Rta)
transactivation of K8 RRE-1 is mediated by an interaction
with DNA-bound C/EBPa (Wang et al., 2003). However, C/
EBPa binding motif is not found in or near K8 RRE-II and -
III. These observations, together with the differential regu-
lation of K8 RRE-I and RRE-II/-III in B cells and 293 cells,
Fig. 8. Activation of K8 DE promoter by ORF50 in 293 cells. K8 DE promoter and its mutants shown in Figs. 6A and 7Awere introduced into 293 cells with
pCR3.1-ORF50 or empty pCR3.1 as described in Materials and methods. Forty-eight hours posttransfection, cells were harvested and lysates were prepared for
assaying luciferase activities. The fold of transactivation was calculated by comparing the normalized firefly luciferase activity of the reporter in pCR3.1-
ORF50-transfected cells with that in pCR3.1-transfected cells.
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activated by ORF50 in different mechanisms.Discussion
Differential expression of K8 gene in IE and DE phases is
controlled by two distinct promoters
In this report, we investigated the regulation of KSHV
K8 gene expression. In the immediate-early and delayed-
early phases of the viral life cycle, two types of messenger
RNAs are transcribed from K8 gene, respectively. We foundthat the differential expression of K8 gene is due to the use
of different promoters. Alternative promoter usage is fre-
quently found as a mechanism to regulate eukaryotic gene
expression. In KSHV, K9 gene (vIRF) was shown to utilize
different promoter elements to regulate its expression during
latency and lytic replication (Chen et al., 2000). K2 (vIL-6)
gene was also reported to be expressed in two lytic tran-
scripts as a result of using two promoters (Deng et al.,
2002). Differential expression of a gene using alternative
promoters probably represents a common mechanism for a
fine-tuning regulation of a gene to meet physiological
requirements in a temporal or spatial fashion. For instance,
the existence of two vIL-6 promoters is believed good for
Y. Wang et al. / Virology 325 (2004) 149–163 159differential regulation of vIL-6 gene expression in cell- and
tissue-specific environment (Deng et al., 2002). Differential
regulation of K8 gene expression in immediate-early and
delayed-early phases is probably related to the multiple
functions of K8 in these two phases.
Because of analogous genome location, similar splicing
pattern and homologous protein structure with respect to
EBV Zta protein, K8 is thought to be the KSHVanalogue of
Zta. EBV Zta protein is a transcriptional activator that
activates viral lytic gene expression cascade and initiates
the switch of EBV from latency to lytic life cycle (Miller,
1990). Zta also binds to EBV lytic DNA replication origin
(OriLyt) and its binding is essential for viral lytic DNA
replication (Fixman et al., 1995). For KSHV K8, its bZip
structure and homology to EBV Zta protein suggest that it is
a regulatory protein and may involve either transcription or
viral lytic replication. Its complicated and highly regulated
splicing pattern suggests its importance to viral life cycles.
Recently, we found that K8 bZip protein binds to a DNA
sequence within the KSHV lytic DNA replication origin
(ori-Lyt) (Lin et al., 2003). Wu et al (2001) reported that K8
is incorporated into KSHV DNA replication compartments
formed with six core KSHV replication proteins. K8 was
also found to cause G1 cell arrest through binding to
CCAAT/enhancer-binding protein-a (CEBP-a), which is a
viral strategy believed to facilitate the progression of viral
DNA replication (Wu et al., 2002). Recently, it was reported
that K8 interacted with ORF50 and repressed the transcrip-
tion of viral delayed-early gene by ORF50 (Izumiya et al.,
2003; Liao et al., 2003). Among these distinct functions of
K8, the functions in modulating ORF50-mediated trans-
activation of viral delayed-early genes and in regulating host
cell cycle and causing G1 phase arrest are believed to be
exerted in immediate-early phase, while the involvement of
K8 in ori-Lyt-dependent DNA replication appears to be a
delayed-early function. We think that the differential regu-
lation of K8 allows a precise control of K8 levels in cells in
different phases to meet the requirements for efficient viral
replication.
K8 IE promoter
Our study on the IE promoter of K8 has identified a few
motifs that are crucial for the promoter activity and respon-
siveness to chemical induction, especially to sodium buty-
rate. Among them are a potential CREB-binding motif
located at position 82 and two potential GC boxes (Sp-1
binding sites) located downstream at 29 and 44. A
mutagenesis study showed that the deletion of CREB motif
did not effect much the responsiveness of the promoter to
butyrate but greatly reduced the basal transcription level (the
transcription activity before the induction by butyrate);
while removal of the region that containing two GC boxes
abolished both basal transcription and responsiveness to
butyrate induction. Two other features of this promoter are
worthy to discuss. First, as shown in the Northern analysis(Fig. 1), K8 IE promoter is tightly restricted in latent phase.
However, K8 DE promoter is found to be loosely controlled
and express in low levels during latency, but its transcription
activity is greatly enhanced when the virus is induced to
lytic life cycle. Many other DE genes such as K9 (vIRF) and
K2 (vIL-6) are expressed in low levels in latency and be
induced to higher transcription level in lytic replication
(Chen et al., 2000; Deng et al., 2002; Sarid et al., 1998).
These genes have been defined as class II gene (Sarid et al.,
1998) and K8 DE gene is apparently one of them. In
contrast, K8 IE promoter is completely silenced during
latency. Besides K8 IE promoter, other IE promoters in-
cluding promoters for ORF50 and ORF48/29b also display
tight controls in their activities during latency (Saveliev et
al., 2002). Second, sequence analysis of K8 IE promoter did
not reveal a TATA box, suggesting that K8 IE promoter is a
TATA-less promoter. Interestingly, a survey of promoter
sequences of other KSHV IE genes including ORF50,
ORF45, and ORF48/29b also showed that these IE pro-
moters are TATA-less promoters. Although a TAAATA
sequence (nucleotide 71452–71457) has been suggested
as a potential TATA box in the ORF50 promoter (Deng et
al., 2000), a recent study showed that mutation of the
TAAATA element did not affect the transcription activity
of the promoter in response to sodium butyrate and TPA
induction (Lu et al., 2003).
Recently, regulation of ORF50 promoter has been inves-
tigated. Like K8 IE gene, ORF50 is controlled by a TATA-
less IE promoter. The results showed that activation of
ORF50 promoter in response to sodium butyrate and tri-
chostatin A (two histone deacetylase inhibitors) is controlled
by GC-box, which is bound by Sp-1 or Sp-3. A stable
nucleosome is positioned over the transcriptional initiation
site with Sp-1/Sp-3 associated at the nucleosomal DNA
entry position (Lu et al., 2003). Because Sp-1 binding sites
in K8 IE promoter are crucial for the promoter activity,
regulation of K8 IE promoter likely shares a similar mech-
anism with that of ORF50 promoter in which Sp-1 serves as
a basal promoter element. Furthermore, these IE promoters
appear to be controlled in a repression fashion during the
latency rather than an induction manner during the reacti-
vation, which is probably a strategy to prevent viral IE
genes from a leaking expression in latent phase.
K8 DE promoter
K8 DE promoter is activated by ORF50 (Rta). The
ORF50-mediated transactivation has been characterized in
several KSHV DE promoters including those for polyade-
nylated nuclear RNA (PAN) (Song et al., 2002), K12
(kaposin) (Chang et al., 2002), ORF57 (Lukac et al.,
2001), and K9 (vIRF) (Ueda et al., 2002). ORF50 exerts
its transactivation through at least two distinct mecha-
nisms, i.e., by binding to DNA and by non-DNA binding
mode. ORF50 responsive elements in PAN, ORF57,
K8DE, and K12 promoters were identified and it was
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tightly (Chang et al., 2002; Lukac et al., 2001; Song et al.,
2002). Among them, RREs in PAN and K12 promoters
share a common consensus motif (Chang et al., 2002;
Song et al., 2002); ORF57 RRE and K8 RRE-I have
sequence similarity. ORF50 was found to act on K8
RRE-I through a manner of direct DNA binding (Lukac
et al., 2001). Two independent RRE elements were iden-
tified in the K9 gene promoter and none of these RREs
was found to be directly bound by ORF50 (Rta). There-
fore, it has been suggested that KSHV Rta activates K9
promoter by a non-DNA-binding mechanism (Ueda et al.,
2002). K8 RRE-II, which is the major cis-acting element
responsive to ORF50, shares a sequence homology with
K9 RRE-II, suggesting that they may share a mechanism
of ORF50 activation. It is very likely that ORF50 activates
the promoter through K8 RRE-II in a non-DNA binding
mechanism. K8 RRE-III represents another type of ORF50
responsive element. It appears to be a bipartite element,
consisting of a consensus sequence similar to K8 RRE-II
and an RBP-Jn binding motif. Liang et al. (2002) reported
that ORF50 activates some viral genes via interaction with
an RBP-Jn. An RBP-Jn binding motif was found in
ORF57 promoter adjacent to an ORF50 responsive ele-
ment (Liang et al., 2002). It is likely that in the ORF57
RRE and K8 RRE-III, an ORF50-RBP-Jn heterodimer
recognizes a bipartite element and binds to DNA in a
shoulder-by-shoulder manner. Taken together, K8 DE pro-
moter might be activated by ORF50 (Rta) through both
DNA binding and non-DNA-binding mechanisms.
It was not surprising to see at least three ORF50 (Rta)
responsive elements in K8 DE promoter because transcrip-
tional synergy by transactivators has been studied in EBV
Zta transactivation system (Chi et al., 1995). However, it
is interesting to find the differential utilization of these
RREs in different cell background to response to ORF50
induction. This phenomenon, together with the notion that
ORF50 activates genes using different mechanisms when
distinct RRE elements are involved, led to a sketchy
model for K8 DE promoter activation by ORF50 (Rta).
In B cells, ORF50 activates K8 DE promoter mainly
through RRE-II by a non-DNA-binding mechanism. It
might be carried out though modulating some cellular
DNA binding protein by either piggybacking on these
cellular proteins or altering their activities or abundance.
In non-B cells, ORF50 uses both RRE-I and RRE-II to
activate K8 DE promoter, probably due to differential
availability of certain cellular factors in different types of
cell. This explains why the promoter with RRE-II deleted
(PK8-DE250D2) can respond to ORF50 in 293 cells,
because ORF50 is able to utilize RRE-I due to the
presence of certain cellular factor(s), which may be either
absent or at a lower level in B cells. Two distinct
mechanisms for ORF50-mediated K8 DE gene activation
may provide an opportunity that allows K8 gene being
activated in different cell environment.Materials and methods
Cell culture
BC-1 (Cesarman et al., 1995b) cells were purchased from
the American Type Culture Collection (ATCC) and grown
in RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD)
supplemented with 15% fetal bovine serum (Gibco-BRL).
BCBL-1 (Renne et al., 1996) cells were obtained from the
NIH AIDS Research and Reference Reagent Program and
grown in RPMI 1640 medium supplemented with 10% fetal
bovine serum. BJAB and BL-41 (both are EBV-negative,
KSHV-negative Burkitt’s lymphoma cell lines) cells were
grown in RPMI 1640 medium supplemented with 10% fetal
bovine serum. Two hundred ninety-three cells were main-
tained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum. All cultures
contained penicillin–streptomycin (50 units/ml) and fungi-
zone (1.25 Ag/ml amphotericin B and 1.25 Ag/ml sodium
desoxycholate).
Chemical induction
BC-1 cells were induced with 3 mM of sodium butyrate
(Sigma, St. Louis, MO). BCBL-1 cells were treated with 20
ng/ml of phorbol-12-tetradecanoate-13-acetate (TPA). When
induction was accompanied by inhibition of protein synthe-
sis, cycloheximide (Sigma) was added in the culture to 50
Ag/ml 4 h before the induction.
Northern blotting and hybridization
Total RNA was isolated from cells using Trizol reagent
(Gibco-BRL) and poly (A+) mRNA was purified using the
PolyAtract mRNA isolation system (Promega). The mRNA
was separated by electrophoresis in 1% agarose/6% formal-
dehyde gel in 20 mM MOPS buffer, pH 7.0. Each lane was
loaded with mRNA from 2  107 cells. The RNA was
transferred to a Nytran membrane and hybridized with a
single-stranded 32P-labeled probe complementary to K8
mRNA. The probe was prepared by asymmetric PCR with
EcoRI-digested pCR3.1-K8a templates and the oligonucle-
otide K8C primer (5VTCAACATGGTGGGAGTGGCGCG-
TCC 3V). The labeling reaction was performed in 15 Al of
reaction solution [1 Taq polymerase buffer, 16.67 AM each
dATP, dGTP, dTTP, 1.67 AM dCTP, 5 Al [a-32P]dCTP (800
Ci/mmol, 10 ACi/Al, Amersham], 100 ng DNA, 20 pmol
primer and 2.5 units Taq polymerase). The PCR initiated with
a denaturing step of 2 min at 94 jC, followed by 15 cycles of
sequential steps of 1 min at 94 jC, 1 min at 50 jC, and 3 min
at 74 jC. Finally, the reaction was extended for 10 min at 74
jC. RNA loading equivalence was controlled by probing
with h-actin cDNA. An RNA ladder (0.24–9.5 kb, Gibco-
BRL) was included in each agarose-formaldehyde gel and
detected in Northern blots by hybridization with labeled
EDNA.
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Reporter plasmids were constructed using the luciferase
reporter plasmid pGL3-Basic (Promega). The constructs are
as follows.
PK8-IE500 was constructed by cloning a PCR-generated
505-bp fragment from KSHV genomic position 74125 to
74629 into SacI/SmaI-digested pGL3-Basic vector. The de-
letion mutants of PK8-IE500 (PK8-IE360, PK8-IE230, PK8-
IE130, and PK8-IE80) were constructed by cloning appro-
priate PCR DNAs or restriction fragments of PK8-IE500 into
pGL3-basic vector. The inserts of these plasmids are illus-
trated in Fig. 4A. PK8-IE230DSp1 was generated using a
PCR-based mutagenesis system, namely ExSite (Stratagene).
In brief, a pair of phosphorylated oligonucleotides toward
opposite directions (K8-19: 5VTGACCGGTTGCAGAAGC-
GTATACTCTC 3V; K8-20: 5V TAACGAGGTACAGGAGT-
CCGGCACACT 3V) were used in a high-fidelity PCR with
PK8-IE230 plasmid as a template. After PCR, the template
DNA (wild-type PK8-IE230) was removed by a complete
digestion with DpnI, which does not degrade PCR-synthe-
sized DNA. The PCR product was self-ligated and used to
transform E. coli competent cells. PK8-IE230DCREB was
constructed in the same way using oligonucleotides K8-15
(5V GCCGGAGACTCCGGGCCGAAGGAAGCG 3V) and
K8-16 (5V GGTGGAGAGTATACGCAACTGCAACCG
3V).
PK8-DE250 was constructed by cloning a PCR-generat-
ed 254-bp fragment from KSHV genomic positions 74596
to 74849 into KpnI/SmaI-digested pGL3-Basic vector. The
deletion mutants of PK8-DE250 (PK8-DE147, PK8-DE114,
PK8-DE95, and PK8-DE58) were constructed by cloning
appropriate PCR DNA or restriction fragments of PK8-
DE250 into pGL3-basic vector. The inserts of these plas-
mids are illustrated in Fig. 6A. PK8-DE250D1 and PK8-
DE147D1 were generated using ExSite system with a pair of
phosphorylated oligonucleotides toward opposite directions
(K8-4: 5V AGGGGGTGGTATTTCCTCCGTTGTCGA 3V;
K8-5: 5V CACAAATAGTCACAATCAACCAGA 3V). Sim-
ilarly, PK8-DE250D2 and PK8-DE147D2 were generated
using ExSite system with phosphorylated oligonucleotides
K8-6 (5V GTTGATTGTGACTATTTGTGAAACA 3V) and
K8-7 (5V GAATCTGTAGGTTAACTCCACTTTGCACC
3V), and PK8-DE250D3 was generated with K8-8 (5V
CAGTTTGGTGCAAAGTGGAGTTAACC 3V) and K8-9
(5V GTTAACGCAGGCACAGACGCC 3V). The deleted
regions in these mutants are illustrated in Fig. 7A.
P50 was constructed by cloning a PCR-generated DNA
fragment of ORF50 promoter sequence into pGL3-Basic
vector. The PCR was performed with primers P50-1 (5V
ATTACCATGGTTGTGGCTGCCTGGACAGT 3V) and
P50-2 (5V ATAACTCGAGCTTCCACGTTGATCCGGCTT
3V). The PCR product was digested with NcoI and XhoI and
cloned into NcoI/XhoI-digested pGL3-Basic vector. The
insert is 1038 bp long corresponding to KSHV genomic
positions 70561 to 71598.
Y. Wang et al. / ViroP59 was constructed by PCR amplification of a 1298-
bp fragment from KSHV genomic positions 96737 to
98034. The primers used in the PCR reaction are P59-1
(5V ATTACCATGGTTGCGGCCGTAGACGCACAG 3V)
and P59-2 (5V ATAACTCGAGGGACCTGCTGCTA-
CATGGATACA 3V). The PCR product was digested with
NcoI and XhoI and cloned into NcoI/XhoI-digested pGL3-
Basic vector.
pCR3.1-ORF50 was constructed by cloning a cDNA
sequence of ORF50 coding region into pCR3.1 vector
(Invitrogen). The cDNAwas generated by reverse-transcrip-
tion-coupled PCR using mRNA from butyrate-induced BC-
1 cells and two specific primers, ORF50N (5V ATGGCG-
CAAGATGACAAGGGTAAGA 3V) and ORF50C (5V
TCAGTCACGGAAGTAATTACGCCAT 3V).
DNA transfection and luciferase assays
To transfect B cells, 10 Ag luciferase reporter construct
and 1 Ag pRL-TK plasmid were mixed with 107 BL-41 cells
in OPTI-MEM medium (GIBCO-BRL) and electroporated
(250V, 960 AF) with a Genepulser II (Bio-Rad, Hercules,
CA). Electroporated cells were then transferred to RPMI
1640 medium supplemented with 10% serum or media
containing sodium butyrate (3 mM), TPA (20 ng/ml), or
ionomycin (0.5 AM), respectively, and grown for 48 h. The
pRL-TK plasmid was included as an internal control, which
constitutively expresses Renilla luciferase. To test the re-
sponse of these promoters to ORF50 (Rta), 10 Ag luciferase
reporter plasmid, 1 Ag pRL-TK, and 3 Ag pCR3.1-ORF50
(or pCR3.1 vector) were cotransfected into BL-41 or BJAB
cells by electroporation. Electroporated cells were grown in
RPMI 1640 medium supplemented with 10% serum and
harvested after 48 h.
To transfect 293 cells, subconfluent cells grown in 24-
well plates were transfected with 100 ng of pGL-3 reporter,
10 ng pRL-TK reporter, and 50 ng pCR3.1-ORF50 using
Qiagen Effectene transfection kit. Cells were harvested at 48
h posttransfection for luciferase assay.
The dual luciferase reporter assay system (Promega) was
used to examine the responsiveness of the promoters to
chemical inducers and ORF50. Transfected cells were
washed once with 1 PBS and suspended in 400 Al of
1 passive lysis buffer. Cells were frozen-thawed once and
centrifuged in mirocentrifuge for 1 min. Supernatants were
assayed for firefly luciferase and Renilla luciferase activities
using a TD-20/20 luminometer with dual auto injector
(Turner Designs). The luciferase assays were carried out
according to the manufacturer’s instruction (Promega).Acknowledgments
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